These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Preiksaitis JK Clin Infect Dis; 2004 Oct; 39(7):1016-23. PubMed ID: 15472855 [TBL] [Abstract][Full Text] [Related]
43. Clonal gammopathies and allogeneic stem cell transplantation. SorĂ F; Laurenti L; Chiusolo P; De Matteis S; Leone G; Sica S Bone Marrow Transplant; 2008 Feb; 41(3):317. PubMed ID: 17982492 [No Abstract] [Full Text] [Related]
44. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Haque T; Crawford DH Springer Semin Immunopathol; 1998; 20(3-4):375-87. PubMed ID: 9870252 [No Abstract] [Full Text] [Related]
46. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214 [TBL] [Abstract][Full Text] [Related]
47. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Styczynski J; Einsele H; Gil L; Ljungman P Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376 [TBL] [Abstract][Full Text] [Related]
54. [Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022)]. ; Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):716-725. PubMed ID: 36709164 [No Abstract] [Full Text] [Related]
55. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956 [TBL] [Abstract][Full Text] [Related]
56. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Ibrahim U; Bassil C; Chavez JC; Khimani F; Jain MD; Locke FL; Osman K; Lazaryan A Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):772-778. PubMed ID: 37263876 [No Abstract] [Full Text] [Related]
57. Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm. Piccin A; Morello E; Svaldi M; Haferlach T; Facchetti F; Negri G; Vecchiato C; Fisogni S; Pusceddu I; Cortelazzo S Hematol Oncol; 2012 Dec; 30(4):210-3. PubMed ID: 22915052 [TBL] [Abstract][Full Text] [Related]
58. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation]. Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188 [TBL] [Abstract][Full Text] [Related]